Correction to: Neuropsychopharmacology (2002) 27, 1071–1081.

The authors wish to apologize for error made in the above paper. The corrected section of text is produced below.

EFFICACY

Except where stated, efficacy data are presented using the ‘maintenance’ population and the last-observation-carried forward (LOCF) procedure (all other analyses yielded similar results).

Arnisulpride was demonstrated to be not inferior to risperidone with respect to the primary efficacy parameter. The PANSS total score decreased markedly in both groups (from 91.1±13.0 at baseline to 58.9±22.6 after 6 months in the amisulpride group and from 92.5±12.2 to 61.1±20.9 in the risperidone group) (Figure 1). The noninferiority analysis showed that the decrease in the PANSS total score from baseline was not inferior with amisulpride as compared to risperidone (90% two-sided confidence interval [−5.6; 4.0]). The two-sided 95% confidence interval also confirms the noninferiority of amisulpride compared with risperidone (Table 3). Similar results were observed in the ITT overall population (from 91.7±12.6 at baseline to 64.8±25.0 after 6 months in the amisulpride group and from 92.9±12.3 to 66.8±24.1 in the risperidone group, 90% two-sided confidence interval [−5.6; 3.7]).